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Background: Amaranthaceae pollen allergy incidence has increased in the last years 
due to the desertification process occurring in many countries. In some regions of Spain, 
Salsola kali is the main cause of pollinosis at almost the same level than olive and grass 
pollen. Sal k 1 -the sensitization marker of S. kali pollinosis- is actually used in clinical 
diagnosis, but it is purified at a low yield from pollen. Thus, the aim of the study 
consists of the production of a recombinant isoform of Sal k 1 able to span the structural 
and immunological properties of the natural isoforms present in S. kali pollen and 
validate its potential use for diagnosis. Methods: Sal k 1-encoding cDNA was amplified 
by PCR, cloned in pET41b vector and used to transform BL21(DE3) E. coli cells to 
produce the recombinant allergen. Immunoblotting, ELISA, basophil activation and 
skin prick test were used to validate the recombinant protein against Sal k 1 isolated 
from pollen. Sera and blood cells from S. kali pollen sensitized patients and anti-Sal k 1 
monoclonal and polyclonal antisera were used. Results: rSal k 1 was produced in E. coli 
with a final yield of 7.5 mg/L of cell culture. The expressed protein was isolated, 
purified to homogeneity, and structurally and immunologically validated against the 
natural form –nSal k 1- isolated from pollen as a useful diagnostic tool. In addition, Sal 
k 1 exhibited a higher IgE cross-reactivity with plant-derived food extracts such as 
peanut, almond or tomato than with related and non-related pollen sources such as P. 
acerifolia and Oleaceae members. Conclusions: rSal k 1 expressed in bacteria 
maintains its structural and immunological properties intact in comparison to nSal k 1. 
rSal k 1 spans the immunological properties of most of the natural isoforms found in 





A wide repertory of plant families produces relevant allergenic pollens [1, 2]. Pollens 
from the Amaranthaceae family are gaining relevance as allergenic inducer in countries 
where the climate change is causing extensive desertification because these resistant 
weeds are able to rapidly colonize these areas [3]. The most relevant members of this 
family in the Mediterranean area are Salsola kali and Chenopodium album [4, 5]. 
Despite the allergenic cross-reactivity observed between these members of the 
Amaranthaceae family [6], about 10 to 30% of the patients are mainly sensitized to S. 
kali [7]. Several allergens from C. album (Che a 1 [8], Che a 2 and Che a 3 [9]) and S. 
kali (Sal k 1 [7], Sal k 2 (accession number: Q8L5K9), Sal k 3 [10], Sal k 4 [11, 12], 
and Sal k 5 [13] pollens have been identified (for a review [14]). Sal k 1 is the allergenic 
marker of S. kali pollen able to discriminate between sensitized and non-sensitized 
patients to this weed [7]. An average prevalence of Sal k 1, a pectin methylesterase 
(PME), in certain areas of Spain is about 18% among all pollen-sensitized patients, and 
about 70% in S. kali pollen sensitized patients, as revealed by the multi-centre study 
(“VEGETALIA” and “EXPO”) [15]. The same cohort of patients showed a prevalence 
of 2% to the major allergen of C. album (Che a 1) in all pollen sensitized patients [15], 
and thus confirming the role of Ole e 1-like protein family as sensitization marker of the 
Amaranthaceae species. 
In addition to Sal k 1, PMEs from olive (Olea europaea) pollen -Ole e 11-, tomato 
(Lycopersicon esculentum) and kiwi fruit (Actinia deliciosa) have also been reported as 
allergens [16-19]. Sal k 1 shares an amino acid sequence identity of 57, 17 and 23% 
with olive pollen, tomato and kiwi PMEs, respectively. Despite this low identity 
observed between PMEs from pollens and plant-derived foods, these proteins possess a 
catalytic core highly conserved during evolution, containing Ala153, Gln173, Asp174, 
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Asp195, and Arg253 residues in Sal k 1. This region might enable PME cross-reactivity 
processes from different sources since a significant IgG recognition could be observed 
when comparing PMEs from olive pollen and other plant-derived food sources such as 
avocado, pear or tomato by immunoblotting [16]. 
Sal k 1 purified from pollen is already being used in commercial diagnostic protocols 
to determine the specific IgE levels of patients to the sensitization marker of S. kali by 
ImmunoCAP (Thermo Fisher Scientific). However, Sal k 1 is purified from pollen at a 
very low yield and with a high number of isoforms. Only 100 µg of homogeneous 
protein can be obtained from 5 g of dried pollen [7]. In addition, a different isoform 
composition is obtained from batch to batch. Then, the availability of a well 
characterized recombinant isoform equivalent to those natural allergenic isoforms 
present in S. kali pollen extract should be a useful tool to standardize diagnostic and 
immunotherapeutic protocols. The recombinant Sal k 1 protein should circumvent batch 
to batch variability and allergenic protein content concentration problems of the S. kali 
natural protein extracts used in these protocols [20, 21].  
In this context, the aim of this work consisted of the production of a recombinant 
isoform of Sal k 1 able to span the structural and immunological properties of the 
natural isoforms present in S. kali pollen, and then, validating its use for the diagnosis of 
S. kali allergy. In addition, we have also found that the PME could be implicated in 





Materials and methods 
 
Protein extracts 
Pollen from several plant species was obtained from ALK-Abelló (Madrid, Spain). 
Pollen protein extracts were prepared by saline extraction as described previously [8]. 
Plant-derived food extracts from fruits and nuts were prepared as previously described 
[22]. Protein extract concentration was determined using the Bicinchoninic Acid Assay 
(Pierce Chemical Co., Thermo Fisher Scientific, Rockford, IL, USA).  
 
Cloning strategy  
PCR amplification of S. kali PME isoform Sal k 1.0103 was performed using the 
template previously cloned in the pCR2.1 vector (Invitrogen, Groningen, The 
Netherlands) [7]. Two specific oligonucleotides were designed: a sense primer with an 
NdeI restriction site (underlined), 5'- actcatATGCAGCCGATCCCCCCT -3' that 
corresponds to the MQPIPP amino acid sequence (the N-terminal end of the mature 
protein), and an antisense primer, 5'- ttactcgagCACTTTAGGTGGTGGTAG -3' with an 
XhoI restriction site (underlined) that corresponds to LPPPKV amino acids (C-terminal 
end of Sal k 1). The amplified PCR product was then digested with NdeI and XhoI 
restriction enzymes and cloned into the pET41b plasmid (Invitrogen) in phase with a 
nucleotide sequence codifying for an 8xHis tag. This sequence is included in the 
expression vector at the C-terminus of the protein.  
 
Expression and purification of rSal k 1 
The construct pET41b/Sal k 1.0103 was used to transform E. coli BL21(DE3) cells to 
produce recombinant Sal k 1 according to [11]. BL21(DE3) cultures were centrifuged at 
6000 g for 20 min and reconstituted in sodium phosphate 20 mM pH 8.0 containing 
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sodium chloride 0.5 M, imidazole 20 mM and phenylmethane-sulfonylfluoride 1 mM. 
After bacterial lysis by three cycles of freezing in N2 and thawing at 42 ºC, the soluble 
fraction containing rSal k 1 was clarified by centrifugation at 12000 g for 20 min, and 
subsequently loaded in an AKTA Purifier FPLC system (GE healthcare, Madrid, Spain) 
with a His-Trap FF crude (GE healthcare) to purify the recombinant protein. The elution 
of the protein was performed using an isocratic gradient of 0.5 M imidazole in 
reconstitution buffer according to [23]. 
 
Sera and antibodies 
Sera from 80 patients suffering from Amaranthaceae pollinosis were collected from 
three regions of Spain: Zaragoza, Murcia and Alicante (online suppl. Table S1). Written 
informed consent was obtained from all patients. The non-atopic controls were selected 
according to a non-allergic history and negative skin prick tests to the usual panel of 
respiratory allergens. 
Rabbit polyclonal antisera (pAb) against the natural PME from S. kali pollen was 
obtained by weekly injections of the protein (100 µg) in complete Freud´s adjuvant. 
Horseradish peroxidase-labeled goat polyclonal antibody against rabbit IgG was 
obtained from Bio-Rad (Richmond, Calif). Mouse monoclonal antibody against human 
IgE and two monoclonal antibodies 1.22.1 (mAb 1) and 1.3.1 (mAb 2) raised against 
nSal k 1 and belonging to different families were obtained in collaboration with ALK-
Abelló (Madrid, Spain). Horseradish peroxidase-labeled goat polyclonal antibody 
against mouse IgG was purchased from Pierce Chemical Co. Horseradish peroxidase-
labeled mouse polyclonal antibody against the His-tag was from Sigma-Aldrich (St 




MS analysis and CD spectroscopy 
MS of purified proteins was performed in a Bruker-Reflex IV MALDI-TOF (Bruker-
Franzer Analytic, Bremen, Germany). The CD spectra recording and deconvolution of 
data was obtained in the far-UV, on a Jasco J-715 spectropolarimeter (Japan 
Spectroscopic Co., Tokyo, Japan) according to [11]. Theoretical percentages of 
secondary structure were obtained with GOR method [24]. 
 
Analytical procedures 
SDS-PAGE was performed in 15% polyacrylamide gels. Proteins were stained with 
Coomassie Blue R-250 (Sigma-Aldrich). Molecular mass determinations were done 
with protein molecular mass markers SM0431 (Fermentas, Thermo Fisher Scientific). 
The concentration of the purified proteins was calculated by measuring the absorbance 
at 280 nm in a DU-7 spectrometer (Beckman, Madrid, Spain) using the theoretical 




Immunoblotting procedures were developed as described previously [11] using 
individual human sera (diluted 1:10), anti-human IgE monoclonal antibody (diluted 
1:3000) and horseradish peroxidase-labeled anti-mouse IgG antibody or a rabbit 
polyclonal antiserum raised against nSal k 1 (diluted 1:50000) followed by horseradish 
peroxidase-labeled anti-rabbit IgG polyclonal antibody (1:3000). Alternatively, a 
horseradish peroxidase-labeled mouse polyclonal antibody against His-tag (1:2000) or 
monoclonal antibodies raised against nSal k 1 (1:200) followed by an horseradish 
peroxidase-labeled anti-mouse IgG antibody (1:2500) were used. For immunoblotting 
8 
 
inhibition assays an equivolumetric pool of sera (n=8) (diluted 1:10) was alternatively 
preincubated with 0, 1 and 5 µg of rSal k 1 or, alternatively, nSal k 1. Protein bands 
were quantified by densitometry using the Multi Gauge Analysis software (Fujifilm, 
Barcelona, Spain) and referring the inhibition percentage to the control without inhibitor 
[13]. 
Indirect ELISA was performed as described [26] in 96-well plates coated with 100 ng 
of purified recombinant protein, 20 μg of pollen extract or 500 ng of pineapple stem 
bromelain [27] (Sigma-Aldrich). OD values >0.1 arbitrary units (mean + 3 x SD of the 
OD of the negative control) were considered positive. Inhibition assays were performed 
with an equivolumetric pool of human sera (n=8) (diluted 1:10), the anti-nSal k 1 
polyclonal antiserum (diluted 1:50000) or monoclonal antibodies raised against nSal k 1 
(1:10000), previously adsorbed to different concentrations of inhibitors ranging from 1 
ng to 5 µg for purified proteins and 20 or 200 µg for the pollen and plant-derived food 
extracts. Binding of human IgE was detected by anti-human IgE monoclonal antibody 
(diluted 1:5000) followed by horseradish peroxidase-labeled anti-mouse IgG antibody 
(diluted 1:2500). The binding of anti-nSal k 1 polyclonal antiserum was detected with 
the horseradish peroxidase-labeled anti-rabbit IgG antibody (1:3000) and binding of 
mouse monoclonal antibodies with the horseradish peroxidase-labeled antibody 
(1:2500). The inhibition percentage was calculated according to the formula: inhibition 
(%) = [1-(Abs492 nm with inhibitor/Abs492 nm without inhibitor)] x 100 [13]. 
 
Basophil activation test (BAT) 
This test was performed as previously described [28]. After blood-cell separation, 50 
μL of each patient’s cell suspension were incubated with 50 μL of indicated protein 
concentration. To evaluate background basal values without stimulation (negative 
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control), we added 50 μL of stimulation buffer (cRPMI), containing IL-3 (2 ng/mL) in 
the cell suspension. As a positive control, a monoclonal anti-IgE anti-receptor antibody 
was used at a final concentration of 1 μg/mL. A positive response was concluded for 







Cloning, recombinant production and purification of rSal k 1 
We previously reported the polymorphic character of Sal k 1 allergen and the 
sequencing of three different isoforms: Sal k 1.0101 (AY590141), Sal k 1.0102 
(AY776249) and Sal k 1.0103 (AY776248), which showed 94 to 99% identity in their 
amino acid sequences [7]. 
Here, we aimed to express, purify and characterize a recombinant isoform of Sal k 1, 
which might be used as a replacement of nSal k 1 in diagnostic protocols. To this end, 
we amplified by PCR the cDNA-encoding mature Sal k 1.0103 without the nucleotide 
sequence codifying for the signal peptide, and cloned into the pCR2.1 vector. The 
cDNA was then subcloned into the expression vector pET41b, and the construct 
subsequently used to transform BL21(DE3) cells to produce Sal k 1 as a protein tagged 
at the C-terminus with a 8xHis sequence. 
Different temperatures and IPTG-induction times were surveyed and the supernatants 
and pellets analyzed by Coomassie Blue staining to determine the optimal conditions to 
produce rSal k 1. The highest yield of soluble recombinant protein was observed at 16 
ºC and 48 h of induction with 1 mM IPTG (fig. 1a). 
After affinity chromatography, fractions containing the recombinant protein purified 
to homogeneity were pooled, dialyzed, concentrated and directly used in subsequent 
experiments. rSal k 1 was obtained with yields of approximately 7.5 mg/L of cell 
culture. The recombinant protein integrity and purity was verified by Coomassie Blue 
staining after SDS-PAGE and by immunostaining after transference to membranes with 
(i) a pool of sera from allergic patients to Salsola kali, (ii) two specific monoclonal 
antibodies (mAb 1 and mAb 2), (iii) one polyclonal antiserum raised against nSal k 1, 
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and (iv) a polyclonal antibody directed against the His-tag (fig. 1b). These experiments 
assessed the high purity of the recombinant allergen. 
Then, we proceeded to structurally and immunologically characterize rSal k 1 in 
comparison to nSal k 1. 
 
Structural characterization of rSal k 1 
We first performed CD analyses using rSal k 1 and nSal k 1 at a concentration of 200 
µg/ml (fig. 2a). Similar CD spectra were obtained for both proteins. We observed a 
higher α-helix content in rSal k 1 (15.7% vs 8.6% for nSal k 1), and minor differences 
in the β-sheet, β−turn and non-periodic structure content (fig. 2b). 
 
Immunological characterization 
We analyzed the antigenic properties of both recombinant and natural Sal k 1 by 
ELISA and WB using two different mouse monoclonal antibodies and a polyclonal 
antiserum raised against nSal k 1. By WB under denaturing conditions, we observed 
that the ability of nSal k 1 and rSal k 1 to bind IgG from the monoclonal antibodies and 
the polyclonal antisera was also equivalent (fig. 2c). ELISA titration of mAb 1, mAb 2 
and the polyclonal antisera with rSal k 1 and nSal k 1 showed that IgG-binding ability 
of both proteins was equivalent, suggesting that the antibodies recognized the epitopes 
in nSal k 1 and rSal k 1 in a similar manner (fig. 2d).  
We also evaluated the allergenic properties of both proteins by ELISA and WB. The 
prevalence of both natural and recombinant proteins was tested using sera of S. kali 
sensitized-patients from three different regions of Spain with significant differences in 
S. kali pollen counts (fig. 3). Recognition frequency was almost equivalent for both 
proteins: nSal k 1 (52%) and rSal k 1 (56%). Glycoprotein bromelain with a 
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carbohydrate very similar to that of plant glycoproteins was tested to identify those sera 
able to recognize the carbohydrate moiety of glycoallergens. Interestingly, only six out 
of the eighty patients tested possessed IgE reactivity against the glycan of bromelain 
(fig. 3a), indicating that the global contribution of the carbohydrate moiety to the IgE 
reactivity of Sal k 1 was not relevant in this case. Correlation values obtained when the 
IgE-binding ability of nSal k 1 and rSal k 1 was compared were quite low for all 
patients (r2=0.45), especially for the population of Zaragoza. Surprisingly, the 
regression analysis of the data seemed to indicate a slightly better IgE recognition of 
rSal k 1 by the sensitized patients than for nSal k 1 in all three populations of sensitized 
patients studied (data not shown). 
Finally, we analyzed the IgE-binding ability of both proteins by WB under denaturing 
conditions to determine the role of the conformational epitopes in the IgE reactivity of 
the sera. We used a random set of twenty of the previously identified ELISA-positive 
sera (fig. 3b). The correlation obtained (r2=0.94), indicated that the IgE binding for the 
two proteins under denaturizing conditions was almost equivalent. 
Collectively, these data indicate that rSal k 1 is able to span the antigenic and 
allergenic properties of Sal k 1 isoforms found in pollen. 
 
Inhibition assays 
We then analyzed the IgG- and IgE-equivalence of nSal k 1 and rSal k 1 by ELISA 
and WB inhibition experiments (fig. 4). 
The IgG binding to rSal k 1 was equivalent to that of nSal k 1 when using two 
monoclonal antibodies, whereas the experiments performed with the polyclonal antisera 
indicated that rSal k 1 was not able to completely inhibit the IgG binding to nSal k 1 
(fig. 4a-c).  
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Regarding the IgE-binding analysis by ELISA, it was observed a 30% reduction in 
the IgE-binding ability of rSal k 1 with respect to nSal k 1 in native conditions. 
Furthermore, WB inhibition analyses of nSal k 1 and rSal k 1 using both proteins as 
inhibitors showed in all cases similar inhibition values, and thus indicating that both 
proteins possessed similar IgE-inhibition capacity under denaturing conditions (fig. 4d). 
 
Basophil activation test 
Three patients (two allergic and one non-atopic control) were selected to perform 
basophil activation test (fig. 5). First, we tested the natural and the recombinant proteins 
by ELISA. A good correlation was observed for rSal k 1 and nSal k 1 (fig. 5a). Then, 
we observed that rSal k 1 and nSal k 1 performed similarly in basophil activation test 
(fig. 5b). At 20 µg/ml of rSal k 1 or nSal k 1, we observed similar results for IgE-
positive patients, whereas at 5 µg/ml one patient showed higher activation of basophils. 
In contrast, the non-atopic control was non-responder at all concentrations and allergen 
tested (fig. 5b). 
 
IgE cross-reactivity 
We tested a panel of pollen and plant-derived food extracts with anti-Sal k 1 
polyclonal antiserum to identify those extracts able to potentially cross-react with rSal k 
1 (fig 6a). Then, we surveyed the extracts described to contain allergenic PME by 
ELISA inhibition experiments to rSal k 1 using a randomly selected pool of 8 sera from 
S. kali sensitized patients (fig. 6b). 
 Regardless the complete inhibition observed with S. kali pollen protein extract, 
Platanus acerifolia (plane tree) pollen protein extract showed the highest IgE-inhibition 
capacity, reaching 25% of inhibition using 200 µg of extract. Other IgG-positive PME 
pollen protein extracts-, Ligustrum vulgare (wild privet), Syringa vulgaris (common 
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lilac) were also able to inhibit the IgE-binding to Sal k 1, reaching 24 and 20% of 
inhibition, respectively. A scarce inhibition was observed with Olea europaea (olive) or 
with the Amaranthaceae counterpart, Chenopodium album (Lamb´s quarter). Regarding 
PME plant-derived food extracts, nuts from Prunus dulcis (almond), Arachis hypogea 
(peanut), Pistacia vera (pistachio) and fruits from Solanum esculentum (tomato), 
Solanum tuberosum (potato) and Pyrus communis (pear) were also shown to cross-react 







The role of Amaranthaceae pollens as important sources of allergy has special 
relevance in countries with a desert climate, high temperatures and dry soil [18], and in 
extensive areas of the south of Europe which have suffered from an increase in the 
desertification process in the last years [4, 5]. Indeed, in south-eastern and central areas 
of Spain, Salsola kali pollen has become one of the first causes of seasonal allergy at 
almost the same level than olive and grass pollinosis [4, 5].  
To date, five allergens from S. kali have been reported: the protein kinase homologue 
Sal k 2 (accession number: Q8L5K9), the methionine synthase Sal k 3 [10], the profilin 
Sal k 4 [11, 12], the Ole e 1-like protein Sal k 5, and the here studied major allergen and 
S. kali specific marker -Sal k 1- [7].  
Sal k 1 is a very polymorphic molecule with multiple protein spots identified by two-
dimensional electrophoresis (online suppl. Fig. S1), with pI ranging from 5.9 to 7.7 and 
different glycosylation patterns [7]. Although this heterogeneity hampers the 
development of a suitable purification procedure to obtain a consistent and reproducible 
batch-to-batch protein, a recombinant approach is especially helpful for this protein. 
Thus, our main concern about the production of Sal k 1 consisted of the obtaining of a 
recombinant protein able to be recognized by all sensitized patients to S. kali. As 
previously reported, non-glycosylated PMEs like that of Diospyros kaki conserved their 
3D-folding and its enzymatic activity when comparing with other glycosylated PME 
[29]. Thus, we expressed Sal k 1-specific cDNA in bacteria because glycosylation 
should not be critical for the 3D-folding of PMEs [29] and it has also been successfully 
used to express other glycosylated allergens, which maintained their structural and 
immunological properties intact [30, 31]. 
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Remarkably, we performed an extensive characterization of rSal k 1 produced in E. 
coli in comparison to nSal k 1 to verify that the recombinant protein possessed similar 
structural and immunological properties than the natural protein isolated from pollen. 
Although we observed slight differences in the secondary structure between rSal k 1 and 
nSal k 1, we determined that the most general structural features such as the percentage 
of lamin β remained in rSal k 1. On the other hand, the antigenic behavior of rSal k 1 
was almost equivalent to nSal k 1 pointing out that the structural similarity between 
both proteins was very high. No significant differences were observed in the IgE-
binding of both proteins under denaturing conditions, while in ELISA we observed that 
IgE binding was similar when both proteins were tested individually, biased towards a 
slightly better recognition to nSal k 1 (about 30% of reduced inhibition ability of rSal k 
1 with respect to nSal k 1) when tested in inhibition experiments. However, the 
differences observed cannot be attributed to a wrong folding of the recombinant protein 
since 37 individual serums gave a better recognition to rSal k 1 and 15 to nSal k 1. 
To determine if these differences in the IgE binding to rSal k 1 and nSal k 1 could be 
attributed to the glycosydic moieties -absent in rSal k 1-, or to conformational epitopes 
absernt in the selected isoform, we also tested bromelain –a protein containing CCD-. 
Only a 6.6% of the patients showed specific IgE directed to the glycosydic fractions 
found in bromelain, and only one patient (1.1% of the population) showed correlation 
between the IgE reactivity to glycosydic moiety and a better recognition of the natural 
protein. Then, we could confirm that the contribution of the glycan moiety to the whole 
IgE-reactivity of nSal k 1 was not relevant in the assayed population, as it has also been 
reported for CCDs in a clinical context [32, 33]. 
Collectively, our results seemed to indicate that differences in the allergenic 
recognition with some bias towards nSal k 1 should be attributed to amino acid changes 
inside of the conformational epitopes due to the polymorphism of the natural protein 
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which are able to induce changes in the affinity and specificity of the IgE antibodies. 
Finally, we further confirmed the equivalence of rSal k 1 and nSal k 1 by BAT. rSal k 1 
was able to induce basophil activation from blood of S. kali pollen-sensitized patients at 
a similar level than nSal k 1, correlating BAT values with the IgE-levels to rSal k 1 and 
nSal k 1 of this selected population of sensitized patients. Remarkably, these data 
confirmed the usefulness of rSal k 1 for in vitro diagnosis. 
We also investigated the potential role of Sal k 1 in cross-reactivity because several 
facts pointed out to a direct association of Sal k 1 with these processes: i) the 
biochemical function of this protein family is associated to a well-conserved catalytic 
amino acid core across species [7, 16], which might be an immunogenic region target of 
IgE from sensitized patients, ii) the existence of allergenic PMEs in pollen -Ole e 11 
with prevalence ranging from 55.9% to 75.6% in three different olive pollen allergic 
populations [16]-, and in plant-derived foods like tomato [17, 18] or kiwi (Act d 7) with 
32% of prevalence [19], and iii) because a higher prevalence of Sal k 1 has been 
recently published in patients sensitized to plant-derived food and pollen than in 
patients only sensitized to pollen [15]. Here, we have confirmed the role of Sal k 1 in 
cross-reactivity as deduced from the inhibition experiments performed with a panel of 
plant-derived food and pollen extracts, which showed percentages of inhibition ranging 
from 9% to 24% with allergenic pollens and 18% to 40% with plant-derived food 
extracts. 
In summary, this work shows that rSal k 1 i) was almost equivalent to nSal k 1 
regarding its physicochemical properties, ii) spanned most of the allergenic properties of 
the natural isoforms present in S. kali pollen, and iii) was almost equivalent to nSal k 1 
at allergenic level as demonstrated through immunological approaches and by histamine 
release. Accordingly, the herein presented data provide evidences that rSal k 1 might 
substitute nSal k 1 in the diagnostic protocols actually used in clinics, and could be 
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Legend to the figures 
Fig. 1. Recombinant expression and purification of Sal k 1. a SDS-PAGE analysis of 
the time-course of the recombinant expression of Sal k 1 in E. coli BL21(DE3) cells at 
indicated temperatures and times of induction with IPTG. b SDS-PAGE of the 
purification process of rSal k 1 and immunostaining of nitrocellulose-blotted proteins 
with: 1, an equivolumetric pool of allergic patients sera; 2 and 3, monoclonal antibodies 
(mAb 1 and mAb 2, respectively); 4, the polyclonal antiserum raised against nSal k 1; 
and 5, the polyclonal antibody against His-tag. FT, flow-through; P, purified rSal k 1. 
Molecular mass markers are shown. 
 
Fig. 2. Structural and antigenic properties of rSal k 1 in comparison to nSal k 1. a 
Circular Dichroism spectra of nSal k 1 and rSal k 1 at a concentration of 200 ng/µl. b 
Percentages of secondary structure of both proteins were obtained by de-convolution 
with GOR method. c SDS-PAGE and immunoblot of nitrocellulose-blotted 200 ng of 
natural and recombinant Sal k 1 with the two monoclonal antibodies (mAb 1 and mAb 
2) and the polyclonal antisera (pAb) raised against nSal k 1. Molecular mass markers 
are shown. d Titration of the mAb 1, mAb 2 and the pAb. ELISA plates were coated 
with 100 ng/well of rSal k 1 or nSal k 1. 
 
Fig. 3. Specific IgE binding of rSal k 1 and nSal k 1. a Determination of the IgE-
binding ability of 80 individual sera from three regions of Spain to rSal k 1 (100 
ng/well), nSal k 1 (100 ng/well) or bromelain (500 ng/well). Correlation coefficient (R2) 
among rSal k 1 and nSal k 1 IgE levels is also shown for each population. b Analysis of 
the specific IgE-binding of 20 sera to 200 ng of nitrocellulose-blotted rSal k 1 or nSal k 
1 after SDS-PAGE under reducing conditions. Molecular mass markers are shown. 
 
Fig. 4. Immunological characterization and validation of rSal k 1 in comparison with 
nSal k 1. a-b mAb 1 and mAb 2; c a polyclonal antiserum; and d an equivolumetric 
pool of eight randomly selected sera were tested by ELISA and immunoblotting to 
determine the IgE-binding inhibition between rSal k 1 and nSal k 1. In the ELISA 
experiments 100 ng/well of protein were coated and indicated amounts of each protein 
as inhibitor were used. In the immunoblotting assays under reducing conditions, 0.5 µg 
of each protein were blotted onto nitrocellulose membranes and 5 µg of inhibitor were 
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used. Percentage of inhibition was calculated by densitometry of protein bands. (I%), 
inhibition percentage; (-), no inhibition; (r), rSal k 1; (n), nSal k 1. 
 
Fig. 5. Sal k 1 specific IgE values and basophil activation assays. a IgE levels 
quantified by ELISA of the two S. kali pollen sensitized patients and the non-atopic 
control. b Stimulation index of basophil activation test of patients allergic to S. kali 
pollen and the non-atopic control are shown. 
 
Fig. 6. Sal k 1 cross-react with PMEs from pollen and plant-derived foods. a Detection 
of PMEs from different pollen and plant-derived food sources by immunoblotting using 
the pAb raised against Sal k 1. 20 µg of different pollen and plant-derived food protein 
extracts were blotted onto nitrocellulose membranes and immunostained with the pAb 
obtained against nSal k 1. Molecular mass markers are shown. b The same pollen and 
plant-derived food protein extracts were tested by ELISA inhibition experiments using a 
pool of sera from allergic patients to S. kali against 0.1 µg/well of rSal k 1. 200 µg of S. 
kali and Betula verrucosa pollen protein extracts were used as positive and negative 
controls, respectively. 






